Skip to main content

Market Overview

Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative

Johnson & Johnson (NYSE: JNJ) kickstarted the large-cap pharma earnings season Tuesday with forecast-beating first-quarter results. The company narrowed its full-year earnings per share guidance but maintained its sales outlook.

The Analysts

Morgan Stanley analyst David Lewis maintained an Equal-weight rating on J&J and upped the price target from $134 to $145.

Raymond James analyst Jayson Bedford maintained an Outperform rating and nudged the price target higher from $145 to $147.

Morgan Stanley: Guidance Looks Conservative

J&J's upwardly revised organic growth guidance of 2.5-3.5 percent primarily reflects the optimistic outlook for the pharma segment but it looks conservative, Lewis said in a Wednesday note.

The analyst estimates 4.2-percent organic growth in pharma for 2019, which reflects a 2-point deceleration for the remainder of the year.

Lewis named the following as pharma headwinds for the remainder of the year:

  • An acceleration in Zytiga declines.
  • A moderation in Concerta sales.
  • Generic/biosimilar competitive threats to Velcade, which is likely to see patent expiration in April outside the U.S., along with Procrit and Tracleer.
  • Greater declines in U.S. Remicade sales.

Balancing out the headwinds, the analyst sees tailwinds from continued expansion in existing franchises like Stelara, Darzalex, and Tremfya, and pipeline contributions from Spravato and Erleada.

"We see our pharma estimates as achievable, if not conservative," Lewis said. 

Notwithstanding the conservative guidance, Morgan Stanley said it prefers to stay on the sidelines due to outsized exposure to pharma, which is facing structural headwinds and talc litigation, rendering a balanced risk-reward profile. 

Raymond James: Valuation Multiples Could Expand

The underlying growth in the first quarter was much better than expected, increasing confidence in Raymond James' estimates, Bedford said in a Tuesday note. 

The analyst noted that the pharma and devices segments saw acceleration in growth that was offset by a deceleration in the consumer segment.

Looking ahead, Bedford said J&J might be pressured by a stiffer forex headwind on revenue growth and the bottom line. Yet better organic growth and a solid first quarter will help the company absorb the incremental headwinds, he said. 

Raymond James models 3-4-percent organic growth over the next two years and made no material changes to its earnings estimates. 

The discount at which J&J shares trade to the diversified peer group and the S&P 500 is warranted, but the multiple has the potential for expansion, according to Raymond James.

The Price Action

After advancing 1.1 percent Tuesday in reaction to the earnings, J&J shares were last seen trading slightly at $137.87 at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Latest Ratings for JNJ

Jan 2021Raymond JamesMaintainsOutperform
Jan 2021Credit SuisseMaintainsOutperform
Jan 2021Morgan StanleyMaintainsOverweight

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings


Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: David LewisAnalyst Color Earnings News Guidance Price Target Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

ETCredit SuisseMaintains13.0
IFRXCredit SuisseMaintains2.8
METCredit SuisseMaintains68.0
FLXNCredit SuisseMaintains14.0
ENPHCapital OneInitiates Coverage On175.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at